Chemomab Therapeutics Ltd DRC
$ 1.74
-6.45%
02 Jun - close price
- Market Cap 13,392,700 USD
- Current Price $ 1.74
- High / Low $ 1.95 / 1.74
- Stock P/E N/A
- Book Value 1.49
- EPS -1.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.71 %
- 52 Week High 5.52
- 52 Week Low 1.35
About
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-03 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.003 | -0.003 | -0.004 | -0.016 | -0.007 | -0.008 | -0.01 | -0.26 | -0.2753 | -0.2654 | -0.02 | -0.036 |
| Estimated EPS | 0 | -0.01 | -0.005 | -0.1 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.02 | -0.03 |
| Surprise | -0.003 | 0.007 | 0.001 | 0.084 | 0.003 | 0.002 | 0 | -0.25 | -0.2453 | -0.2454 | 0 | -0.006 |
| Surprise Percentage | None% | 70% | 20% | 84% | 30% | 20% | 0% | -2500% | -817.6667% | -1227% | 0% | -20% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2026-06-02 20:10:17
Chemomab Therapeutics has announced significant changes to its board and committee leadership. Gwen Melincoff has been appointed as an independent Class I director and chair of the nominating and governance committee, expanding the board to five directors. These changes follow the resignations of directors Claude Nicaise and Jill Quigley, and the subsequent appointments of Neil Cohen (as chair) and Nissim Darvish to the audit committee, along with a reorganization of the nominating and governance committee.
2026-06-01 11:40:03
Chemomab Therapeutics Ltd. (CMMB) CEO Mor George Adi purchased 9,804 American Depositary Shares (ADS) on the open market on May 29, 2026. The purchases involved two transactions: 4,926 ADS at $2.08 and 4,878 ADS at $2.05. This insider buying activity, totaling approximately $20,246, signals a positive sentiment from the Chief Executive Officer regarding the company's prospects.
2026-05-19 13:09:25
Chemomab Therapeutics Ltd. is poised to present its lead drug candidate, Nebokitug, at a European medical congress. Nebokitug is a first-in-class monoclonal antibody targeting CCL24, a protein involved in inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases. The company aims for Nebokitug to potentially become the first approved therapy for primary sclerosing cholangitis.
2026-05-18 09:09:29
Chemomab Therapeutics reported Q1 2026 financial results, including an $8.0 million cash position with a runway through Q1 2027, and a reduced net loss. The company also announced new data from its Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC), showing significant reductions in fibrotic and inflammatory pathways, particularly in PSC patients with co-existing inflammatory bowel disease (IBD). These findings suggest nebokitug could offer a differentiated therapeutic benefit for patients with both conditions.
2026-05-15 03:39:54
Chemomab Therapeutics reported a first-quarter loss per share of 0.3 cents, as indicated by the >CMMB stock ticker. This brief financial update provides key information on the company's recent performance.
2026-05-14 19:09:09
Chemomab Therapeutics announced its Q1 2026 financial results, reporting a net loss of $1.8 million and cash reserves to fund operations through Q1 2027. The company highlighted new clinical data for nebokitug, showing promising effects in treating primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). This data suggests nebokitug could be the first FDA-approved disease-modifying treatment for PSC, with plans for a Phase 3 trial underway.
